Trials / Completed
CompletedNCT06630117
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older Participants (60 to 79 Years Inclusive).
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 245 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | V330 | Intramuscular injection |
| BIOLOGICAL | Placebo | Intramuscular injection |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2025-10-17
- Completion
- 2025-10-17
- First posted
- 2024-10-08
- Last updated
- 2025-11-03
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06630117. Inclusion in this directory is not an endorsement.